drugset / Trial / NCT00954226
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase Ib trial studies standard-dose or high-dose erlotinib hydrochloride before surgery in treating patients with head and neck cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2009-08-05
- Primary completion
- 2025-04-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Erlotinib | Small molecule | 200 mg | Oral |
| Subject | Erlotinib | Small molecule | 300 mg | Oral |